# Compass Therapeutics (CMPX) — Earnings

CMPX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cmpx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.14 |
| EPS estimate | −$0.12 |
| EPS surprise | −12.90% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 11, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1738021/000117184325005261/cmpx20250630_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/format/6a80de86-62ee-92a2-9650-f95388b9a5ef.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 11, 2025 | −$0.12 | −$0.14 | -12.90% | — | — |
| Q1 2025 | May 8, 2025 | −$0.11 | −$0.12 | -9.09% | — | — |
| Q4 2024 | Feb 27, 2025 | −$0.10 | −$0.11 | -12.13% | — | — |
| Q3 2024 | Nov 12, 2024 | −$0.11 | −$0.08 | 29.14% | — | — |
| Q2 2024 | Aug 12, 2024 | −$0.10 | −$0.10 | -3.73% | — | $875,000.00 |
| Q1 2024 | May 13, 2024 | −$0.11 | −$0.08 | 29.14% | — | — |
| Q4 2023 | Mar 21, 2024 | −$0.09 | −$0.11 | -16.65% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.11 | −$0.08 | 25.30% | — | — |
| Q2 2023 | Aug 3, 2023 | −$0.08 | −$0.09 | -10.57% | — | — |
| Q1 2023 | May 4, 2023 | −$0.11 | −$0.06 | 43.56% | — | — |
| Q4 2022 | Mar 15, 2023 | −$0.11 | −$0.10 | 10.15% | — | — |
| Q3 2022 | Nov 9, 2022 | −$0.11 | −$0.12 | -14.29% | — | — |
| Q2 2022 | Aug 1, 2022 | −$0.08 | −$0.08 | 3.50% | — | — |
| Q1 2022 | May 9, 2022 | −$0.10 | −$0.07 | 31.97% | — | — |
| Q4 2021 | Mar 18, 2022 | −$0.09 | −$0.15 | -64.11% | — | — |
| Q3 2021 | Nov 12, 2021 | −$0.11 | −$0.10 | 9.09% | — | — |

## Frequently Asked Questions

### When did Compass Therapeutics (CMPX) last report earnings?

Compass Therapeutics last reported on Aug 11, 2025, covering fiscal Q2 2025.

### Did CMPX beat earnings estimates?

No. Compass Therapeutics reported EPS of −$0.14 for Q2 2025 against a −$0.12 estimate — a 12.90% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).